Biospherics Acquires Global Patent Rights from University of Kentucky Research Foundation to Develop Tagatose as a Trigylcerides Therapy

BETHESDA, Md., June 30 /PRNewswire-FirstCall/ — Spherix
Incorporated (Nasdaq: SPEX), an innovator in biotechnology for therapy
in diabetes, metabolic syndrome, and atherosclerosis; and providers
of technical and regulatory consulting services to food,
supplement, biotechnology and pharmaceutical companies, today
announced that its wholly-owned subsidiary, Biospherics
Incorporated, has signed a license agreement with the University of Kentucky Research Foundation
(UKRF). The agreement gives Biospherics the worldwide rights to
international patents filed on behalf of UKRF for Dtagatose as a
lipid-lowering agent for prevention and treatment of
atherosclerosis, hypertriglyceridemia, and related
dyslipidemias.

Also included in the license are five unique drug formulations
that include Dtagatose as one of the active pharmaceutical
ingredients for treatment of atherosclerosis and the metabolic
syndrome. The international patent applications are filed under the
PCT (Patent Cooperation Treaty). A majority of the world’s
countries are signatories to the PCT, including all of the major
industrialized countries (with a few exceptions such as Argentina and Taiwan). As of September 28, 2009, there were 142
contracting states to the PCT.

“Spherix believes that D-tagatose has good potential as a
treatment for the underserved triglyceride market,” said Dr. Claire Kruger, CEO of Spherix.
“Preliminary results from our single-blinded Phase 2 clinical trial
in diabetes show that low doses of D-tagatose significantly lowered
triglyceride levels in people with only mildly

‘/>”/>

SOURCE